The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The soluble CD40 ligand sCD154 in systemic lupus erythematosus
Open accessAbstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by prominent lymphocyte activation, resulting in production of pathogenic IgG autoantibodies such as anti-double-stranded DNA antibody (anti-dsDNA Ab).Such autoantibodies may play a critical role in the progression of lupus nephritis (1).Whereas low amounts of low-affinity anti-dsDNA Ab also can be detected in the sera of healthy adults, high serum titers of anti-dsDNA Ab's of the IgG isotype are found nearly exclusively in patients with SLE.Moreover, the levels of such IgG anti-dsDNA Ab's appear related to disease activity.Aberrant expression of immune costimulatory molecules may contribute to this pathophysiology.Studies indicate that the blood lymphocytes of SLE patients often express higher levels of immune accessory molecules, such as CD54, CD80, CD86, and CD95, than the blood lymphocytes of normal adults (2-5).High-level expression of CD80 or CD86 may contribute to pathologic presentation of self antigens to T cells and/or the production of pathologic anti-DNA autoantibodies.Consistent with this notion, the production of pathologic autoantibodies by lupusprone New Zealand black (NZB) and New Zealand white (NZW) F 1 mice can be ameliorated by CTLA4-Ig (6, 7), a recombinant protein that can block CD80/CD86↔CD28 interactions (8).This has led to speculation that aberrant expression of these costimulatory molecules may contribute to the T-cell activation seen in patients with this disease.Normal B cells can be induced to express immune costimulatory molecules by activated T cells.Activated CD4 T cells can express CD40 ligand (CD154), a molecule that can engage CD40 on the B-cell surface (9).This triggers a cascade of events that ultimately results in expression of a variety of heretofore nonexpressed stimulatory surface accessory molecules, such as CD80 (B7-1) (10-15).High-level expression of CD154 has also been detected on T cells from patients with active SLE, indicating that such cells may have exaggerated expression of this stimulatory molecule (16,17).Conceivably, the exaggerated expression of CD154 could account for the high-level expression of immune accessory molecules on B cells of patients with active disease.Moreover, high-level expression of CD154 may be required for disease activity, which appears to be the case in animal models of SLE.Early et al., for example, reported that the anti-dsDNA Ab production in NZB/NZW F1 mice could be suppressed by treatment with anti-mouse CD154 antibody in vivo (18).Also, lpr/lpr mice made genetically defective in their ability to express CD154 did not develop IgG rheumatoid factor or anti-dsDNA (19).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685 · cited 1×
“Consistent with this notion, the production of pathologic autoantibodies by lupusprone New Zealand black (NZB) and New Zealand white (NZW) F1 mice can be ameliorated by CTLA4-Ig (6, 7), a recombinant protein that can block CD80/CD86↔CD28 interactions (8).”
Background
Cited by
Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus
Blanco, P., Palucka, A. K., Gill, M., Pascual, V., & Banchereau, J. (2001) · Science · doi:10.1126/science.1064890 · Cited by 1,266
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease
André, P., Nannizzi-Alaimo, L., Prasad, S. K., & Phillips, D. R. (2002) · Circulation · doi:10.1161/01.cir.0000028962.04520.01 · Cited by 567
Cauwe, B., Van den Steen, P. E., & Opdenakker, G. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701340019 · Cited by 381
Jacobi, A. M., Odendahl, M., Reiter, K., Bruns, A., Burmester, G. R., Radbruch, A., Valet, G., Lipsky, P. E., & Dörner, T. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10949 · Cited by 361
Kalunian, K. C., Davis, J. C., Merrill, J. T., Totoritis, M. C., Wofsy, D., & for the IDEC‐131 Lupus Study Group (2002) · Arthritis & Rheumatism · doi:10.1002/art.10681 · Cited by 336
CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation
Inwald, D. P., McDowall, A., Peters, M. J., Callard, R. E., & Klein, N. J. (2003) · Circulation Research · doi:10.1161/01.res.0000070111.98158.6c · Cited by 333
Autoimmunity through Cytokine-Induced Dendritic Cell Activation
Banchereau, J., Pascual, V., & Palucka, A. K. (2004) · Immunity · doi:10.1016/s1074-7613(04)00108-6 · Cited by 293
Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model
Rowland, S. L., Riggs, J. M., Gilfillan, S., Bugatti, M., Vermi, W., Kolbeck, R., Unanue, E. R., Sanjuan, M. A., & Colonna, M. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132620 · Cited by 281
Danese, S., Katz, J. A., Saibeni, S., Papa, A., Gasbarrini, A., Vecchi, M., & Fiocchi, C. (2003) · Gut · doi:10.1136/gut.52.10.1435 · Cited by 257
Cardiac biomarkers and the case for point-of-care testing
McDonnell, B., Hearty, S., Leonard, P., & O'Kennedy, R. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.01.019 · Cited by 254
Arce, E., Jackson, D. G., Gill, M. A., Bennett, L. B., Banchereau, J., & Pascual, V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.2361 · Cited by 252
Almerighi, C., Sinistro, A., Cavazza, A., Ciaprini, C., Rocchi, G., & Bergamini, A. (2009) · Cytokine · doi:10.1016/j.cyto.2008.12.009 · Cited by 221
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
Barrile, R., van der Meer, A. D., Park, H., Fraser, J. P., Simic, D., Teng, F., Conegliano, D., Nguyen, J., Jain, A., Zhou, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1054 · Cited by 138
“5–15 ng/mL).(42) Blood from four donors treated with or without Hu5c8, sCD40L, or both (Hu5c8/sCD40L) was perfused through the lumen of the microengineered vessel at a flow rate of 60 lL/min, yielding a wall shear stress of 5 dyne/cm(2), which is comparable to values found in veins under physiological conditions.”
MethodLleo, A., Liao, J., Invernizzi, P., Zhao, M., Bernuzzi, F., Ma, L., Lanzi, G., Ansari, A. A., Coppel, R. L., Zhang, P., et al. (2012) · Hepatology · doi:10.1002/hep.24630 · Cited by 133
Mobarrez, F., Vikerfors, A., Gustafsson, J. T., Gunnarsson, I., Zickert, A., Larsson, A., Pisetsky, D. S., Wallén, H., & Svenungsson, E. (2016) · Scientific Reports · doi:10.1038/srep36025 · Cited by 85
Metadata
- Authors
- Kato, K., Santana-Sahagún, E., Rassenti, L. Z., Weisman, M. H., Tamura, N., Kobayashi, S., Hashimoto, H., & Kipps, T. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1999-10-01
- Volume
- 104
- Issue
- 7
- Pages
- 947-955
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1969979568
- Cited by
- 196
- References
- 1
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.